عنوان

Immunoconjugate Therapy of Hematologic Malignancies

شابک

1461530768

شابک

9781461530763

شماره

b551293

عنوان اصلي

Immunoconjugate Therapy of Hematologic Malignancies

نام عام مواد

[Book]

نام نخستين پديدآور

edited by Steven T. Rosen, Timothy M. Kuzel.

محل نشرو پخش و غیره

Boston, MA

نام ناشر، پخش کننده و غيره

Springer US

تاریخ نشرو بخش و غیره

1993

نام خاص و کميت اثر

(xiii, 205 pages)

عنوان فروست

Cancer treatment and research, 68.

متن يادداشت

1. Radioimmunotherapy of lymphoma --;2. High-dose radioimmunotherapy of lymphomas --;3. Treatment of leukemia with radiolabeled monoclonal antibodies --;4. Imaging and dosimetry determinations using radiolabeled antibodies --;5. New approaches to radiolabeling monoclonal antibodies --;6. Immunotoxin therapy of lymphoma --;7. Immunotoxins for the therapy for graft versus host disease --;8. Recombinant fusion toxins --;A new class of targeted biologic therapeutics --;9. Chimeric antibodies for the treatment of hematologic malignancy --;10. Use of bispecific autibodies in the therapy of tumors.

متن يادداشت

The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.

موضوع مستند نشده

Medicine.

موضوع مستند نشده

Oncology.

شماره رده

نشانه اثر

مستند نام اشخاص تاييد نشده

edited by Steven T. Rosen, Timothy M. Kuzel.

مستند نام اشخاص تاييد نشده

Steven T Rosen

مستند نام اشخاص تاييد نشده

Timothy M Kuzel

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y